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Abstract
Gastric cancer (GC) is a common disease with few effective treatment choices and poor prognosis, and has the
second-highest mortality rates among all cancers worldwide. Dysregulation and/or malfunction of ion channels or
aquaporins (AQPs) are common in various human cancers. Furthermore, ion channels are involved in numerous
important aspects of the tumor aggressive phonotype, such as proliferation, cell cycle, apoptosis, motility, migration,
and invasion. Indeed, by localizing in the plasma membrane, ion channels or AQPs can sense and respond to
extracellular environment changes; thus, they play a crucial role in cell signaling and cancer progression. These
findings have expanded a new area of pharmaceutical exploration for various types of cancer, including GC. The
involvement of multiple ion channels, such as voltage-gated potassium and sodium channels, intracellular chloride
channels, ‘transient receptor potential’ channels, and AQPs, which have been shown to facilitate the pathogenesis
of other tumors, also plays a role in GC. In this review, an overview of ion channel and aquaporin expression and
function in carcinogenesis of GC is presented. Studies of ion channels or AQPs will advance our understanding of
the molecular genesis of GC and may identify novel and effective targets for the clinical application of GC.
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Background
Gastric cancer (GC) remains as a highly lethal malig-
nancy worldwide, particular for developing country,
which makes it a key public health problem [1–3]. High
incidence regions include Asia, Eastern Europe and
Middle and South America [4]. Complete remission of
early GC by surgical or even minimal invasion
endoscopic resection removal is now possible as a result
of developments in therapeutic techniques [5]. Neverthe-
less, the majority of GC patients are asymptomatic only
until entering an advanced stage. Common therapeutic
options include surgery, radiotherapy, and chemotherapy
[6, 7]. Studies have shown that patients with advanced
stage GC have a poor prognosis with a 5-year survival rate
less than 30% [8]. Recently, advances in the biology and
molecular profiling of GC have resulted in targeted
treatments and better survival rates in select patients with
advanced GC. Trastuzumab and ramucirumab are two
new therapeutic targeted drugs that have been approved
in the last 5 years for the treatment of advanced GC [9].
However, the development of more highly effective and
selective targeted agents is still an important issue for the
appropriate management of advanced GC and more re-
search is needed to further improve outcome.
Ion channels and aquaporins (AQPs) are comprised of
transmembrane proteins that regulate the permeation of
specific ions or water between the extracellular and
intracellular environments. Ion channels or AQPs form
rapid cell signals in excitatory tissues by modifying ion
fluxes at various sites within cells on various time scales.
Ion channels and AQPs also contributed to slower
processes, such as volume regulation, proliferation,
apoptosis, migration, invasion and cell adhesion in non-
excitable cells [10–14]. It has become increasingly clear
over the last 15 years that splicing, dysregulated expres-
sion and/or function of ion channels and/or AQPs exists
in many types of cancers and this leads to multiple can-
cer processes (Figs. 1 and 2). In addition, ion channels
and AQPs may modulate cell activities and control many
key aspects of neoplastic progression. They may also de-
termine the fate of these cells. Therefore, ion channels
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that have an impact on cancer development and/or pro-
gression are called “oncogenic channels” [15]. Many stud-
ies from different laboratories have shown that adjustment
of ion channels or AQPs by either altered expression or
inhibited activity can weaken the growth and/or migration
of cancer cells. This means ion channels or AQPs could
become pharmaceutic targets in GC management [16].
The primary aim of this review was to provide an up-
date of recent advances on the role of ion channels and
AQPs in GC. The final objective was to assess the po-
tential use of ion channels in the clinical management of
GC and to evaluate the possibility of ion channels to be
pharmacological targets for GC.
Potassium channels
Potassium (K+) channels have the greatest amount of di-
versity among ion channels and aquaporin in the plasma
membrane, which are encoded by over 75 distinct genes.
There are four main classes according to their activation
mechanisms and domain structure. They are: calcium-
activated K+ channels (KCa), voltage-gated K
+ channels
(Kv), inward-rectifier K
+ channels (Kir) and two-pore-
domain K+ channels (K2P). The voltage-dependent K+
channel (Kv) family can be subdivided into Kv1-4
channels (Shaker, Shab, Shaw and Shal-like subunits),
the silent Kv5, Kv6, Kv8 and Kv9 subunits (regulators),
Kv7 channels (KCNQ), and Kv10-12 channels (EAG-like)
[17, 18]. Potassium channels in non-excitable cells are
likely involved in mediating intracellular Ca2+ concentra-
tions, cell volume, pH homeosis, apoptosis, cell cycle
and differentiation [19]. Many studies have shown that
ectopic expression of K+ channels occurs in human can-
cers. There are four main classes of K+ channels that
have been involved in oncological processes [20]. As an
example, intermediate-conductance calcium-activated
potassium (SK4) channels have been identified to over-
express in triple-negative breast cancer. They are also
implicated in proliferation, apoptosis, migration and
epithelial-to-mesenchymal transition (EMT) processes of
cancer cells [21]. Kir2.1 regulates tumor cell proliferation
and drug resistance by modulation of multidrug resist-
ance protein 1 (MRP1). It is also simultaneously regu-
lated by miR-7 and the Ras/mitogen-activated protein
kinase (MAPK) pathway in small-cell lung cancer [22].
Meanwhile, it has been shown that TREK-1, which is in
the K2P family, is overexpressed in prostate cancer. High
levels of TREK-1 were positively related to T staging and
Gleason scores. They were also associated with shorter
castration resistance free survival. In addition, TREK-1
Fig. 1 Representative ion channels or aquaporins associated with malignant behavior of tumor cells
Fig. 2 Multiple characteristics of ion channels and aquaporins under
different stimuli and showing different responses
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knockdown significantly attenuated prostate cancer cell
proliferation both in vitro and in vivo. Also, TREK-1 in-
duced a G1/S cell cycle arrest [23]. Kv9.3 in colon cancer
showed similar results [24].
Various K+ channels have been shown to play an im-
portant role in GC progression, particularly the human
enter a go-go related potassium channel (hERG1), which
is also known as Kv11.1 and belongs to the EAG family.
hERG1 has been demonstrated to be negatively
expressed in the surrounding non-cancerous tissues;
however, this switched to abnormally positive expression
in GC tissues according to immunohistochemistry ana-
lysis. This indicated that hERG1 is a potential biomarker
for GC [25]. hERG1 expression levels have also been
correlated with TNM stage, grading, lymph node
involvement, tumor differentiation and vascular endo-
thelial growth factor (VEGF)-A expression. hERG1 has
also been shown to enhance GC cell invasion and prolif-
eration, induce cell cycle progression in vitro, and pro-
mote tumor genesis and growth in vivo. Furthermore,
hERG1 modulates VEGF-1 secretion through an AKT-
dependent pathway [26, 27]. Of significance, hERG1 has
been demonstrated to be necessary for cisplatin induc-
tion of apoptosis in GC and may provide a new potential
target for cisplatin chemotherapy [28]. In addition to
hERG1 participating in GC cell behavior, other K+ chan-
nels are also crucial in GC. Kir2.2 knockdown results in
senescence-induced mitochondrial dysfunction. This
dysfunction includes increases in the mitochondrial
mass and reactive oxygen species (ROS) production, as
well as decreases in the mitochondrial membrane poten-
tial and ATP levels in GC [29]. Also, Kv4.1 was demon-
strated to affect cell cycle distribution and facilitate cell
proliferation [30]. KCa (the detailed subtype is not
known) is possibly involved in hepatocyte growth factor
(HGF)-induced GC cell proliferation [31]. Similarly,
KCNQ1 and Kv1.5 were identified to be involved in GC
progression [32, 33]. There have not been any reports,
however, on the role of K2P in GC.
In summary, different K+ channels can remarkably
affect various aspects of GC cell behaviors both in vitro
and in vivo. Therefore, the clinical potential of K+ chan-
nels should be studied further, especially regarding
underlying cell signaling pathways.
Chloride channels
In a study by Jentsch et al., chloride (Cl−) channels were
divided into 6 categories based on the opening mecha-
nisms of the channels: 1) the cystic fibrosis transmem-
brane conductance regulator (CFTR), which is a cAMP-
activated Cl− channel, 2) voltage-gated Cl− channels
(ClCs), which are gated in a voltage-reliant manner, 3)
Ca2+-activated Cl− channels (CACCs), which are
dependent on intracellular calcium, 4) volume-regulated
Cl− channels (VRACs), which are also called swelling-
activated Cl− channels, 5) a family of p64-related
proteins (CLICs), which are putative intracellular Cl−
channels, and (6) γ-aminobutyric acid and glycine recep-
tors, which are ligand-gated Cl− channels. The primary
functions of Cl− channels are regulation of trans-epithelial
transport, volume (osmoregulation), membrane potentials
and cellular immune responses [34]. They were shown to
be critical for tumor progression in several studies. C1C3
has been proposed to promote cervical cancer cell mem-
brane ruffling, which is required for tumor metastasis and
may be a valuable prognostic biomarker and therapeutic
target [35]. Studies on nasopharyngeal carcinoma cells
showed similar results [36]. Meanwhile, Ca2+-activated Cl−
channel transmembrane protein 16A (TMEM16A, also
known as ANO1) could promote breast cancer pro-
gression by activating calmodulin-dependent protein
kinase (CAMK) and epidermal growth factor receptor
(EGFR) signaling [37]. It may also act on cell invasion
and proliferation, and tumor growth in non-small cell
lung cancer [38]. In colon and pancreatic cancer, it
seems that CLIC1 may be a putative oncogene and
may play a pivotal role in tumor progression [39, 40].
In GC, intracellular Cl− has been suggested to regulate
lysosomal acidification and autophagy functions, which
indicated an important role of Cl− in GC progression
[41]. CLIC1 has been shown to be involved in GC devel-
opment and, importantly, CLIC1 was considered to be a
possible prognostic marker for GC. Its expression levels
in GC samples were increased relative to adjacent non-
cancerous mucosa, and were associated with the TNM
stage, perineural invasion, lymph node metastasis and a
5-year survival rate [42]. In addition, elevated CLIC1 ex-
pression was implicated to accelerate the invasion and
migration of GC cells in vitro. This is possibly mediated
by proteasome activator 28β subunit (PA28β), which
then affects the ROS-mediated p38 MAPK signaling
pathway [43, 44]. However, it is intriguing that high
CLIC1 expression could also enhance apoptosis and in-
hibit proliferation [45]. There is also evidence that
TMEM16A was involved in GC progression. TMEM16A
was significantly amplified and upregulated in GC speci-
mens. The overexpression of TMEM16A was positively
associated with disease stage and negatively associated
with patient survival, identifying it as an independent
prognostic factor for patient outcome [46]. The upregu-
lation of TMEM16A could be due to the transcriptional
factor and activator of transcription 6 (STAT6) binding
to its promoter region in response to IL-4 [47]. Few
studies, however, have investigated how TMEM16A
modulated downstream activity.
In conclusion, the involvement of CLIC1 and TMEM16A
channels in GC cell migration, invasion and disease progres-
sion has been demonstrated. Nevertheless, more studies are
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required to determine whether other Cl− channels play a
role in GC progression. Also, studies are needed to increase
knowledge of the mechanistic side of Cl− channel patho-
physiology and in vivo experiments should be performed.
Calcium channels
The “transient receptor potential” (TRP) channels include
a wide variety of ion channels. The majority are permeable
to divalent and monovalent cations and they influence
calcium (Ca2+) homeostasis. There are seven subfamilies
of TRP channels that comprise the vanilloid receptor re-
lated (TRPV), classical (TRPC), and melastatin-related
(TRPM) channels [48, 49]. These channels play an import-
ant role in the cell cycle, which often occurs by regulating
gene transcription. Also, these channels influence other
cellular processes such as apoptosis, proliferation and cell
motility [50]. An increasing number of reports have
shown TRP channels are involved in tumor progression.
In breast cancer, high levels of TRPM7 have been con-
firmed to independently predict poor outcomes and
TRPM7 is functionally required for metastasis in a mouse
xenograft model. In terms of mechanisms, TRPM7 regu-
lates myosin II-based cellular tension. This then regulates
the focal adhesion number, polarized cell movement and
cell-cell adhesion [51]. Meanwhile, TRPV2 was higher in
prostate cancer with metastatic cancer (stage M1) relative
to primary solid tumors (stages T2a and T2b). TRPV2 has
been demonstrated to facilitate the growth of prostate
cancer cells and their invasive properties. It also upregu-
lated expression of invasive enzymes such as matrix
metalloproteinase-2 (MMP2), MMP9 and cathepsin B in
vitro and in nude mice [52]. Furthermore, TRPC6 was
shown to be essential for glioma development through
modulation of G2/M phase transition. It therefore could
be a new target for glioma therapeutic intervention [53].
Store operated Ca2+ entry (SOCE), which is consti-
tuted by pore forming Ca2+ channel subunits Orai1,
Orai2 and/or Orai3, and also their modulators STIM1
and/or STIM2, is critical for Ca2+ oscillation, except for
the TRP channels that have been implicated in Ca2+
homeostasis in cells [54]. Orai1 and STIM1 have been
shown to be highly expressed in tumor cells, and may
contribute to malignant biological behaviors. For ex-
ample, Orai1/STIM1 expression and/or function are ele-
vated in therapy resistant ovary carcinoma cells, which is
at least in part due to increased AKT activity. Also, this
may influence therapy resistance in these cells [55]. In
addition, Orai1 and STIM1 are crucial for breast cancer
cell migration in vitro and tumor metastasis in vivo [56].
In GC, TRPM7 plays an influential role in the growth
and survival of GC cells. It can also depress cell apop-
tosis and is likely to be a potential target for pharmaco-
logical therapy of GC [57, 58]. TRPV6 mediates
capsaicin-induced apoptosis in GC cells. The abundance
of TRPV6 in GC cells determines life or death after cap-
saicin treatment [59]. The TRPC6 channels are essential
for GC cell proliferation and the G2/M phase transition
in vitro, and also for the development of GC in nude
mice [60]. Moreover, we showed that intracellular Ca2+
is elevated in GC cells. Also, store-operated Ca2+ cur-
rents are found in GC cells. The composite molecules of
SOCE; i.e., Orai1 and STIM1 suggest a poor outcome for
GC by advancing tumor cell proliferation, metabolism,
migration, and invasion through targeting metastasis-
associated in colon cancer-1 (MACC1) [61].
In summary, the data suggest that upregulation of
certain subtypes of Ca2+ channels contribute to GC
tumorigenesis, progression and, possibly, drug resist-
ance. Ca2+ channels are therefore potential drug targets
for GC.
Voltage-gated sodium channels
Voltage-gated sodium (Na+) channels (VGSCs) consist
of a pore-forming α subunit, typically crosslinking with
one or more, identical or different, smaller β subunits
[62]. Nine genes in humans (SCN1A to SCN5A, and
SCN8A to SCN11A) code for nine distinct VGSC
proteins (Nav1.1 to Nav1.9, respectively) associated with
differences in their α subunits [63]. These proteins allow
voltage-dependent activation of sodium current, and are
also responsible for membrane depolarization, which is
thought to be specific in cells characterized as being “ex-
citable”, such as skeletal cells, cardiac muscle cells and
neurons [64]. Over the last 15 years, an increasing num-
ber of studies have shown the expression of these chan-
nels in non-excitable cells. In these cells, they affect
physiological functions such as endocytosis, phagocyt-
osis, secretion, motility, and cell proliferation and differ-
entiation [65–68]. There has been a rapid expansion of
published studies documenting the expression of VGSCs
in many cancers. Also, their role in the regulation of cel-
lular invasion and migration and, importantly, their po-
tential use as diagnostic and/or therapeutic targets has
also been studied [69]. In colon cancer, Nav1.5 is overex-
pressed and is a vital controller of a gene transcriptional
system that regulates cell invasion [70]. In non-small cell
lung cancer, Nav17 is required for the epidermal growth
factor (EGF)-mediated extracellular signal-regulated kin-
ase 1/2 (ERK1/2) pathway to enhance cell invasion [71].
Likewise, in cervical cancer, overexpressed Nav1.6 has
been correlated with increased tumor cell invasion [72].
In GC, our results indicated that Nav1.7 was the most
abundantly expressed VGSC subtype in both GC tissues
and GC cell lines. Nav1.7 expression was shown to be fre-
quently higher in GC tissues compared to non-malignant
samples. Nav1.7 expression was correlated to GC patient
prognosis and also with the transporter Na+/H+
exchanger-1 (NHE1) and the oncoprotein MACC1
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expression. Inhibition of Nav1.7 led to reduced NHE1 ex-
pression. This ultimately resulted in a slower rate of GC
cells invasion and proliferation in vitro and tumor growth
in nude mice. Nav1.7 suppression was also associated with
decreased expression of MACC1, and MACC1 suppres-
sion resulted in decreased NHE1 expression. The study
results demonstrated that Nav1.7 controls GC cell inva-
sion and proliferation by MACC1-mediated upregulation
of NHE1. Therapies that specifically target Nav1.7 might
successfully impede GC progression [73]. However, there
have been no other reports on VGSCs in GC.
In summary, despite that our data suggested that func-
tional Nav1.7 expression have broad influence on the
pathophysiology of GC, the available evidence remains
limited. Further studies on both the basic and clinical as-
pects are needed. Also, these studies should extend to
other intracellular mechanisms and assess whether
Nav1.7 is related to drug resistance.
AQPs
AQPs are part of a special superfamily of membrane inte-
gral proteins, which are known as major intrinsic proteins.
AQPs can transport water and sometimes water and
glycerol (“aquaglyceroporins”). They therefore can regu-
late cell volumes and can regulate body water homeostasis
[74, 75]. AQP0 to AQP12 of this family were reported.
They were divided into three subgroups based on their
main sequences: water selective (AQP0, 1, 2, 4, 5, 6, and
8), aquaglyceroporins (AQP3, 7, 9, and 10), and supera-
quaporins (AQP11 and 12) [76]. AQPs have been shown
to be crucial for malignancy. AQP3, for example, induced
ERK1/2 activation. This then increases MMP-3 expression
and secretion, and therefore controls prostate cancer cell
invasion and motility [77]. AQP4 has been implicated to
be upregulated in glioma specimens and plays a critical
role in glioma-associated edema [78]. AQP5 has been
shown to be overexpressed in breast cancer and it possibly
acts on cell proliferation and migration [79]. In addition,
AQP8 has been shown to be involved in cervical cancer
progression [80].
GC tissues express obviously higher levels of AQP3
compared to normal gastric mucosa. Also, upregulation
of AQP3 was related to EMT-associated proteins and
may predict poor outcome for GC. AQP3 regulated GC
cell proliferation, invasion and migration. It also can in-
duce an alteration in expression levels of EMT-related
proteins and MMPs through the PI3K/AKT/SNAIL
signaling pathway in vitro [81]. In addition, AQP3 can
transport glycerol, which is required for GC cell energy
production and lipid synthesis [82]. As for its upstream,
a study reported that c-Met could modulate AQP3
expression through the ERK1/2 signaling pathway in GC
[83]. Moreover, miR-874 suppresses AQP3 expression by
binding to the 3’UTR of AQP3 mRNA in GC cells [84].
Also, human EGF induced AQP3 expression in a time-
and dose-dependent manner in GC cells [85]. An
additional AQP subtype that has been demonstrated to
play a role in malignant biological behaviors of GC cells
is AQP5. The overexpression of AQP5 was observed in
GC tissues relative to the paired normal tissues, accord-
ing to a study by Huang et al. This upregulation was cor-
related with enhanced lymph node metastasis according
to immunohistochemistry. In vitro, overexpression of
AQP5 significantly promoted, while knockdown of
AQP5 notably inhibited the capacity of GC cell prolifer-
ation and migration [86]. Also, AQP5 upregulation may
play a role in GC cell differentiation [87]. These results
indicated that modulation of AQP5 expression or func-
tion may be a potential treatment for GC even though
the detailed mechanisms by which AQP5 promotes GC
progression is unknown.
In conclusion, there is a possibility that AQP channels
have clinical potential for the treatment of GC, as is the
case with other cancers. Yet, further studies are needed
to reveal other subtypes of AQP channels that partici-
pate in tumor progression and provide insight into the
pathophysiological aspects of GC more deeply. Also,
more in vivo experiments are required to support the
above-mentioned findings.
Pharmacological targeting of ion channels and
AQPs for cancer therapy
The above paragraphs have shown the crucial role of ion
channels and AQPs in tumor progression. Thus, using
specific pharmacological modulators of ion channels or
AQPs may pave the way for novel cancer therapy. For
example, treatment with margatoxin (MgTX), which is a
selective inhibitor of Kv1.3, or short hairpin RNA against
Kv1.3, notably attenuated non-small cell lung cancer cell
proliferation and altered cell cycle progression. The use
of MgTX in a lung adenocarcinoma model for 7 days
obviously lessened tumor volume by 75%. Injection of
MgTX into the tumor tissues of nude mice significantly
increased p21 expression level and significantly de-
creased cycline D3 and CDK4 expression levels, indicat-
ing this blocker controls the cell cycle at G1-S in vivo,
which was similar to the in vitro cultured system [88].
Likewise, as an antagonist of TRPM8, cannabigerol
(CBG) inhibited cell proliferation, induced cell apoptosis
and stimulated ROS production in colon cancer cells. In
an in vivo study, nude mice were subcutaneously
injected with colon cancers cells. CBG (3 mg/kg or
10 mg/kg given intraperitoneally every day) used as
treatment produced a dramatic reduction from day 3 of
treatment to the end of the experiment [89]. Also, the
VGSC-blocking drug phenytoin suppressed the invasion
and migration of breast cancer cells in vitro. Phenytoin
treatment also significantly reduced cancer cell invasion
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into the surrounding mammary tissue and tumor growth
in vivo. Phenytoin significantly inhibited metastasis to the
lungs, liver and spleen [90]. In addition, a decrease in
CLIC1-mediated Cl− currents and glioblastoma cell prolif-
eration were also seen with CLIC1 antibody addition.
Meanwhile, glioblastoma cells exposed toisotype control
antibodies or CLIC1 antibodies were transplanted into the
brains of immunodeficient mice. CLIC1 antibody treat-
ment led to smaller tumors and significantly improved
overall survival in mice. This indicated treatment with
CLIC1 antibodies produces an obvious decrease in in vivo
tumorigenicity of glioblastoma cells [91].
There are a number of inhibitors of AQPs that may be
useful in treating tumors other than the above-
mentioned inhibitors of ion channels (the structure of
some inhibitors of AQPs are shown in Fig. 3) [92–94].
In colon cancer, for example, inhibition of AQP1 by
AqB013 effectively reduced tumor cell migration and in-
vasion as well as endothelial tube formation [95]. In pan-
creatic cancer, inhibition of AQP3 by the inhibitor
CuSO4 attenuated tumor cell migration, which sug-
gested it was a potential therapeutic treatment agent for
pancreatic cancer [96]. Meanwhile, there are a few pat-
ents that have been filed that represent small molecule
AQP modulators and pharmaceutical formulations, such
as WO2013005170 (metal-based inhibitor of aquaglycero-
porins AQP3, AQP7, and AQP9), US8835491 (modulator
of orthodox aquaporin AQP1), and WO2008052190
Fig. 3 The structures of some aquaporin inhibitors are shown. a Structure of sulfonamide-based compounds that act as AQP1 and AP4
modulators. b Structure of AQP2 and AQP4 phenylbenzamide-type inhibitors and associated pro-drug salts. c Gold(III) complexes that can
be selective aquaglyceroporin inhibitors
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(modulators of orthodox aquaporin AQP4) that may be
used in therapeutic applications in the clinic [92].
As illustrated in the above examples of other types of
cancer, this relatively new area of study has already led to
the identification of potential therapeutic drugs for GC.
With the use of hERG1 inhibitor E4031 daily for 2 weeks
starting from the day after inoculum in in vivo experi-
ments, the masses were notably decreased with E4031
treatment, which was paralleled by the decrease in tumor
angiogenesis. In addition, within the masses in E4031-
treated mice, there was a reduction in VEGF-A expression
and AKT prosphoralation, which strongly confirmed the
in vitro data [26]. SKF96365, an agent known to block
TRPC channels, also stagnated the GC cell cycle in the
G2/M phase and inhibited cell proliferation in vitro. Ap-
plication of SKF96365 (20 mg/kg) for 5 successive days
through intraperitoneal injection after 7-day implantation
led to reduced tumor volume in vivo [60]. Our study
showed the VGSC inhibitor tetrodotoxin (TTX) decreased
MACC1 and NHE1 expressions, which decreased the
extracellular pH and increased the intracellular pH. This
affected the GC cell proliferation and invasion in vitro
[73]. However, we did not use TTX in the experiments on
mice, which should be done in the future.
Since the set of ion channels that promote GC devel-
opment is now known, it is imperative to conduct in-
depth research on the specific ion-channel targeting
drugs. Furthermore, the potential side-effects should be
addressed.
Conclusions and future perspectives
Conclusions
The primary conclusions of this review are the following:
1) many ion channels and AQPs are differentially
expressed in GC tissues and cells relative to normal
gastric mucosal specimens and cells. 2) Changes in the
expression or activity of ion channels or AQPs give the
GC cells a pathological character and the ion channels
then affect various aspects of the malignant behavior of
GC cells, such as proliferation, migration and invasion.
3) Multiple signaling pathways may be activated by ion
channels and AQPs and this could enhance a variety of
oncogenes, thereby contributing to GC tumorigenesis
and progression. 4) Inhibiting the expression or blocking
the activity of ion channels or AQPs impairs GC cell
function both in vitro and in vivo, which could open a
new avenue for pharmaceutical research in GC. We
therefore suggest that ion channels could be realistic,
functional biomarkers and new therapeutic targets in
GC, as in many other cancers.
Future perspectives
Much more work needs to be done on GC from multiple
aspects. Firstly, the ion channels or AQPs that have
already received attention require further characterization.
Moreover, other ion channels or AQPs that might be
possibly important are worth investigation. Secondly,
angiogenesis, lymphangiogenesis, autophagy dysregula-
tion, and the Warburg effect are ubiquitous in GC, and
these phenomena are regulated by ion channels and/or
AQPs in many other types of cancer. Therefore, whether
ion channels and/or AQPs affect the above-mentioned
phenomena in GC should also be determined. Crociani et
al. showed that HERG1 regulated VEGF-A expression and
angiogenesis in GC and a combined treatment with
hERG1 inhibitors and antiangiogenic drugs could enhance
the therapeutic effect and repress tumor growth [26].
Dong et al. demonstrated that AQP3 promotes cisplatin
resistance in GC cells through autophagy [97]. There have
been no additional reports, however, about the relation-
ship between ion channels/AQPs and the other above-
mentioned phenomena in the progression of GC. Thirdly,
the detailed mechanisms or other factors that are involved
in GC processes should be explored further even though
some signaling pathways or oncogenes have been con-
firmed to participate in the contribution of ion channels
to GC progression. In addition, ion channels or AQPs
may be regulated by growth factors such as EGF, HGF,
VEGF, nerve growth factor (NGF) and fibroblast growth
factor (FGF), as well as the hormones estrogen and insulin
[30, 71, 98–102] (Fig. 2). However, the research on the up-
stream of the ion channels or AQPs is still limited, which
attenuates our understanding of how the ion channels or
AQPs are upregulated and/or activated. Fourth, albeit
many previous reports showed circumstantial evidence,
there is a conspicuous insufficiency of studies that have
utilized site-directed mutagenesis to change the biophys-
ical properties of the related currents. Meanwhile, KO
mouse models may also assist with establishing the facility
of these interesting proteins, which is absent in the
present studies. Finally, and importantly, specific blockers
or antagonists that specifically act on certain subtypes of
ion channels or AQPs and have few side effects should be
developed to translate basic research findings into clinical
applications. The currently available agents primarily in-
fluence a variety of ion channel or aquaporin subtypes;
however, these agents are not specific, which can lead to
clinically adverse effects that limit their usage. Thus, there
is an urgent need to develop drugs that target specific sub-
types of ion channels or AQPs. Furthermore, large-scale
studies should evaluate whether these agents have protect-
ive function over the long-term in GC patients.
In summary, the use of ion channels or AQPs as diag-
nostic, prognostic, or therapeutic targets for GC is
possible. K+ channels (hERG1, Kir2.2, Kv4.1, KCNQ1,
and Kv1.5), Cl
− channels (CLIC1, and TMEM16A), Ca2+
channels (TRPM7, TRPV6, TRPC6, and Orai1), Na+
channels (Nav1.7), and AQPs (AQP3, and AQP5) may be
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potential candidate markers for GC. Further research
and rigorous evaluation are needed to determine which
is better for use in the clinic. Although progress has
been made in this area, much work remains to be con-
ducted. Furthermore, the exploration of pharmacological
agents for ion channels may enable the development of
therapies for GC.
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